The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: A systematic review and bayesian network meta-analysis

Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD). However, it is unclear which PARPi is optimal in mCRPC patients with HRD in 2nd -line setting.